HNC
MCID: HDN003
MIFTS: 56

Head and Neck Cancer (HNC)

Categories: Cancer diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Head and Neck Cancer

MalaCards integrated aliases for Head and Neck Cancer:

Name: Head and Neck Cancer 11 19 5 41 14 75
Head and Neck Neoplasm 11 5
Head and Neck Neoplasms 43
Tumor of Head and Neck 11
Head and Neck Tumours 11
Head/neck Neoplasm 11
Cancer, Head/neck 38
Hnc 14

Classifications:



External Ids:

Disease Ontology 11 DOID:11934
MeSH 43 D006258
NCIt 49 C3077
SNOMED-CT 68 255055008
UMLS 71 C0018671

Summaries for Head and Neck Cancer

MedlinePlus: 41 Head and neck cancer includes cancers of the mouth, nose, sinuses, salivary glands, throat, and lymph nodes in the neck. Most begin in the moist tissues that line the mouth, nose, and throat. Symptoms include: A lump or sore that does not heal A sore throat that does not go away Trouble swallowing A change or hoarseness in the voice Head and neck cancers are twice as common in men. Using tobacco or alcohol increases your risk. In fact, around 75% of head and neck cancers are linked to tobacco use, including smoking and smokeless tobacco. Infection with HPV is a risk factor for some head and neck cancers. To diagnose head and neck cancer, your doctor will do a physical exam and diagnostic tests. You will have a biopsy, where a sample of tissue is taken out and examined under a microscope. It is the only test that can tell for sure if you have cancer. If found early, these cancers are often curable. Treatments may include surgery, radiation therapy, chemotherapy, or a combination. Treatments can affect eating, speaking or even breathing, so patients may need rehabilitation. NIH: National Cancer Institute

MalaCards based summary: Head and Neck Cancer, also known as head and neck neoplasm, is related to squamous cell carcinoma, head and neck and squamous cell carcinoma. An important gene associated with Head and Neck Cancer is MIR205 (MicroRNA 205), and among its related pathways/superpathways are Endometrial cancer and Malignant pleural mesothelioma. The drugs Dopamine and Benzydamine have been mentioned in the context of this disorder. Affiliated tissues include lymph node, salivary gland and skin, and related phenotypes are neoplasm and no phenotypic analysis

Disease Ontology: 11 An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.

Wikipedia: 75 Head and neck cancer develops from tissues in the lip and oral cavity (mouth), larynx (throat), salivary... more...

Related Diseases for Head and Neck Cancer

Diseases related to Head and Neck Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1030)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma, head and neck 33.9 TP53 PIK3CA MIR99A MIR31 MIR210 MIR21
2 squamous cell carcinoma 33.1 TP53 PIK3CA MIR205 MIR199A1 FGFR2 EGFR
3 oropharynx cancer 33.0 TP53 PLAG1 PIK3CA MIR99A MIR21 MIR199A1
4 thyroid gland cancer 32.9 TP53 PIK3CA MIR199A1 EGFR
5 larynx cancer 32.9 TP53 MIR31 MIR210 MIR21 MIR204 MIR196A1
6 salivary gland carcinoma 32.8 TP53 PLAG1 EGFR CDKN2A
7 nasopharyngeal carcinoma 32.8 TP53 PIK3CA MIR99A MIR31 MIR21 MIR205
8 laryngeal benign neoplasm 32.8 TP53 PIK3CA EGFR CDKN2A
9 esophageal cancer 32.7 TP53 PIK3CA MIR99A MIR31 MIR21 MIR205
10 lip and oral cavity cancer 32.7 TP53 PIK3CA MIR31 MIR21 EGFR CDKN2A
11 oral cavity cancer 32.6 MIR99A MIR31 MIR210 MIR21 MIR205 MIR204
12 hypopharynx cancer 32.5 TP53 PRB4 EGFR CDKN2A
13 pharynx cancer 32.5 MIR99A MIR31 MIR21 MIR205 MIR204 MIR199A1
14 oral squamous cell carcinoma 32.4 MIR99A MIR31 MIR21 MIR205 MIR204 MIR199A1
15 tongue carcinoma 32.3 TP53 MIR99A MIR31 MIR21 MIR139 EGFR
16 lung cancer 32.2 TP53 PLAG1 PIK3CA MIR99A MIR31 MIR210
17 skin carcinoma 32.1 TP53 MIR31 MIR21 MIR199A1 EGFR CDKN2A
18 laryngeal squamous cell carcinoma 32.1 TP53 MIR21 MIR139 EGFR CDKN2A
19 lymphatic system disease 32.1 TP53 MIR31 MIR210 MIR21 MIR205 MIR204
20 adenoid cystic carcinoma 32.0 TP53 PIK3CA EGFR CDKN2A
21 peripheral nervous system disease 31.9 TP53 MIR31 MIR21 MIR199A1 MIR196A1 MIR145
22 colorectal cancer 31.9 TP53 PIK3CA MIR99A MIR31 MIR210 MIR21
23 melanoma 31.9 TP53 PIK3CA MIR31 MIR210 MIR21 MIR205
24 cervical cancer 31.9 TP53 PIK3CA MIR31 MIR210 MIR21 MIR205
25 breast cancer 31.8 TP53 PIK3CA MIR31 MIR210 MIR21 MIR205
26 gastric cancer 31.8 TP53 PIK3CA MIR21 MIR204 MIR199A1 MIR196A1
27 ovarian cancer 31.8 TP53 PIK3CA MIR99A MIR31 MIR210 MIR21
28 human papillomavirus infectious disease 31.7 TP53 PIK3CA MIR31 MIR21 MIR199A1 MIR196A1
29 skin squamous cell carcinoma 31.7 TP53 MIR21 FAT2 EGFR CDKN2A
30 adenocarcinoma 31.7 TP53 PIK3CA FGFR2 EGFR CDKN2A
31 colonic benign neoplasm 31.6 TP53 PIK3CA MIR21 MIR199A1 MIR145 EGFR
32 cerebrovascular disease 31.6 MIR210 MIR21 MIR199A1 MIR145
33 tongue squamous cell carcinoma 31.6 TP53 MIR99A MIR210 MIR21 MIR204 MIR199A1
34 tonsil cancer 31.6 TP53 PLAG1 PIK3CA MIR199A1 EGFR CDKN2A
35 diabetes mellitus 31.5 TP53 MIR99A MIR210 MIR21 MIR145 EGFR
36 small cell cancer of the lung 31.5 TP53 PIK3CA MIR21 EGFR CDKN2A
37 lip cancer 31.5 TP53 MIR205 CDKN2A
38 cervical squamous cell carcinoma 31.5 TP53 PIK3CA EGFR CDKN2A
39 lung squamous cell carcinoma 31.5 TP53 PIK3CA MIR196A1 MIR145 MIR139 FGFR2
40 bladder cancer 31.5 TP53 PIK3CA MIR99A MIR31 MIR21 MIR205
41 hematologic cancer 31.5 MIR31 MIR210 MIR21 MIR204 MIR199A1 MIR196A1
42 spinal cord disease 31.5 TP53 MIR205 MIR199A1 MIR196A1 MIR139 EGFR
43 glioblastoma 31.4 TP53 PIK3CA MIR210 MIR21 GAS5 FGFR2
44 myocardial infarction 31.4 TP53 MIR210 MIR21 MIR204 MIR199A1 MIR145
45 atypical teratoid rhabdoid tumor 31.4 TP53 EGFR CDKN2A
46 li-fraumeni syndrome 31.4 TP53 PIK3CA EGFR CDKN2A
47 renal cell carcinoma, nonpapillary 31.4 TP53 PIK3CA MIR99A MIR31 MIR210 MIR21
48 pancreatic cancer 31.4 TP53 PIK3CA MIR99A MIR31 MIR210 MIR21
49 chordoma 31.4 TP53 MIR31 MIR210 EGFR CDKN2A
50 leukemia, acute lymphoblastic 31.4 TP53 MIR210 MIR21 MIR199A1 MIR196A1 CDKN2A

Graphical network of the top 20 diseases related to Head and Neck Cancer:



Diseases related to Head and Neck Cancer

Symptoms & Phenotypes for Head and Neck Cancer

MGI Mouse Phenotypes related to Head and Neck Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.5 CDKN2A EGFR FGFR2 MIR139 MIR31 PIK3CA
2 no phenotypic analysis MP:0003012 9.28 CDKN2A EGFR FGFR2 MIR196A1 MIR199A1 MIR205

Drugs & Therapeutics for Head and Neck Cancer

Drugs for Head and Neck Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 611)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
2
Benzydamine Approved Phase 4 642-72-8 12555
3
Methadone Approved Phase 4 76-99-3, 1095-90-5 4095
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
5
Diclofenac Approved, Vet_approved Phase 4 15307-86-5, 15307-79-6 3033
6
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
7
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
8
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
9
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
10
Dopexamine Approved, Investigational Phase 4 86197-47-9 55483
11
Dobutamine Approved Phase 4 34368-04-2 36811
12
Meperidine Approved Phase 4 57-42-1 4058
13
Citalopram Approved Phase 4 59729-32-7, 59729-33-8 2771
14
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
15
Ofloxacin Approved Phase 4 82419-36-1 4583
16
Venlafaxine Approved Phase 4 99300-78-4, 93413-69-5 5656
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
18
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
19
Histamine Approved, Investigational Phase 4 51-45-6 774
20
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
21
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
22
Mitomycin Approved Phase 4 50-07-7 5746
23
Arginine Approved, Investigational, Nutraceutical Phase 4 74-79-3 6322
24
Dexetimide Withdrawn Phase 4 21888-98-2 30843
25 Cathartics Phase 4
26 Carboxymethylcellulose Sodium Phase 4
27 Laxatives Phase 4
28 Dopamine Agents Phase 4
29 Analgesics, Opioid Phase 4
30 Narcotics Phase 4
31 Pharmaceutical Solutions Phase 4
32 Anesthetics, Intravenous Phase 4
33 Anesthetics, General Phase 4
34 Cardiotonic Agents Phase 4
35 Hemostatics Phase 4
36 Omega 3 Fatty Acid Phase 4
37 Epinephryl borate Phase 4
38 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
39 Bronchodilator Agents Phase 4
40 Respiratory System Agents Phase 4
41 Antitussive Agents Phase 4
42 Adrenergic beta-Agonists Phase 4
43 Anti-Asthmatic Agents Phase 4
44 Dopamine agonists Phase 4
45 Mydriatics Phase 4
46 Cytochrome P-450 Enzyme Inhibitors Phase 4
47 Cola Phase 4
48 Acidophilus Phase 4
49 Bifidobacterium Phase 4
50 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 2147)
# Name Status NCT ID Phase Drugs
1 The Effect on an Ionic Silver Dressing in Head and Neck Patients With Malignant Fungating Wound Unknown status NCT00813631 Phase 4
2 A Comparison of Oral Controlled-release Morphine With Transdermal Fentanyl in Nasopharyngeal Cancer Patients With Moderate or Severe Oral Mucositis Pain Induced by Chemoradiotherapy Unknown status NCT04292990 Phase 4 Fentanyl;Morphine
3 Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy Unknown status NCT02484677 Phase 4 Cisplatin;Docetaxel;5-Fluorouracile
4 A Randomized Study on the Effects of Lactobacillus Brevis CD2 in the Prevention of Radio and Chemotherapy Induced Oral Mucositis in Head and Neck Cancer Patients. Unknown status NCT01707641 Phase 4
5 Effectiveness of Low Energy Laser Treatment in Oral Mucositis Induced by Chemotherapy and Radiotherapy in Head and Neck Cancer Unknown status NCT01876407 Phase 4
6 EVALUATION OF THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS IN HEAD AND NECK CANCER PATIENTS Unknown status NCT02241876 Phase 4 N-acetylcysteine
7 Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Therapy Combined With Chemotherapy and Radiotherapy in Treament of Head and Neck Cancer in Advanced Stage Unknown status NCT00894153 Phase 4 chemotherapy plus p53;chemotherapy
8 An Exploratory Prospective, Open-label, Unicentric Study With Cross-over Design, Comparing Lymphoseek® vs. Albumin Nanocolloid for Image- Guided Sentinel Lymph Node Mapping in Head and Neck, Melanoma and Breast Cancer. Unknown status NCT04261179 Phase 4 Lymphoseek;Nanocoll
9 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
10 Phase 4 Study Evaluating Efficacy, Safety and Acceptability of Treatment With a New Salivary Equivalent Compared to Two Moisturizing Mouth Sprays on the Improvement of Dry Mouth Symptoms and Oral Comfort in Patients With Xerostomia. Completed NCT02049112 Phase 4
11 Phase IV Study on the Feasibility of a Preventative/Therapeutic Approach With Benzydamine Oromucosal Solution in Radiation-induced Oral Mucositis (OM) in Patients With Head and Neck Cancer (HNC) Completed NCT05055726 Phase 4 Benzydamine Hydrochloride 0.15% w/v oromucosal solution
12 The Effect of Norepinephrine and Dopamine on Radial Forearm Free Flap Tissue Oxygen Pressure and Microdialysate Metabolite Measurements Completed NCT02241083 Phase 4 Dopamine;Norepinephrine
13 Open-Label Prospective Trial Evaluating the Toxicities Associated With Subcutaneous Administration of Ethyol (Amifostine) for the Prevention of Radiation-Induced Toxicities Completed NCT00158041 Phase 4 Amifostine administered subcutaneously
14 Does Continuous Popliteal Nerve Block Improve Pain Management for Patients Undergoing Major Maxilla or Mandible Resection With Microvascular Reconstruction Using a Free Fibula Graft Completed NCT03607227 Phase 4 Levobupivacaine;Saline Solution
15 Effect of Enteral Immunonutrition During Chemoradiotherapy in Patients With Head and Neck Cancer or Esophageal Cancer Completed NCT00333099 Phase 4
16 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
17 An Open-Label Study Using the Medpulser® Electroporation System to Treat Head and Neck Cancer Completed NCT00198263 Phase 4
18 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® Completed NCT01553032 Phase 4 Erbitux®
19 An Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery: A Randomised Study Completed NCT01418118 Phase 4 Epinephrine;Norepinephrine;Dobutamine;Dopexamine
20 Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients: A Randomized Clinical Trial Completed NCT02926573 Phase 4 Gabapentin;Placebo
21 A Prospective Randomized Study of LigaSure Small Jaw® Versus Conventional Neck Dissection in Head and Neck Cancer Patients Completed NCT02597582 Phase 4
22 Prevention of Depression in Patients Being Treated for Head and Neck Cancer Completed NCT00536172 Phase 4 Escitalopram;Placebo
23 Comparison Between Two Regimens of Chemotherapy Concurrent With Radiotherapy in Locally Advanced Head and Neck Cancer Completed NCT03998696 Phase 4 Cisplatin 40 mg/m2;Cisplatin 100 mg/m2
24 The Multi-center,Open-label,Single Arm Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Patients With Lung Cancer,Head and Neck Cancer,Colorectal Cancer,Ovarian Cancer and the Other Cancer Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
25 Treatment of Pain in Head-and-Neck Cancer Patients: is Methadone More Effective Than Fentanyl? Completed NCT01317589 Phase 4 fentanyl;methadone
26 Clinical Evaluation of a Salivary Substitute and a Mucoprotective Product on Xerostomia in Head-and-neck Cancer Patients Completed NCT01316393 Phase 4
27 Absorption of Orally Ingested Phosphate in Head and Neck Cancer Patients With and Without Refeeding Syndrome Completed NCT02880072 Phase 4
28 Phase IV Clinical Study Evaluating The Efficacy of Chemoradiotherapy Following Neoadjuvant Treatment With Docetaxel and Cisplatin in Indifferentiated and Non-keratinized Squamous Cell Carcinoma of Nasopharynx Completed NCT00772681 Phase 4 docetaxel and cisplatin
29 Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Oropharyngeal and Maxillofacial Cancer Patients Eligible Surgery Completed NCT02622880 Phase 4
30 A Pilot Randomised Comparison of Bicarbonate Based Mouth Care Versus Biotene Based Mouth Care During Radiotherapy Completed NCT00138827 Phase 4 Biotene (mouth care)
31 Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
32 Evaluation of Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy Completed NCT02869321 Phase 4 Fentanyl;Morphine Sulfate;Fentanyl placebo;Morphine Sulfate placebo
33 Individual Nutritional Support With High Protein Formula With Modified Sensory Component for H&N Cancer Patients on Chemo and Radiotherapy Recruiting NCT05046028 Phase 4
34 Study on the Treatment of Refractory and Locally Advanced Head and Neck Malignant Tumor With Anlotinib Hydrochloride Capsules Combined With Chemoradiotherapy Recruiting NCT04507035 Phase 4 Anlotinib hydrochloride capsules
35 Clinical Study of the Effects of Compound Kushen Injection on Radiation-induced Oral Mucositis in Head and Neck Cancer Patients. Recruiting NCT04204382 Phase 4 Levofloxacin Injection;Compound Kushen Injection(CKI)
36 Intestinal Function of Patients With Colon Neoplasia, Airways and Upper Digestives Subjected to Surgical Treatment: Impact of the Use of Symbiotics Recruiting NCT04874883 Phase 4
37 Serotonin-Norepinephrine Reuptake Inhibitors for the Prevention and Treatment of Pain, Depression, and Anxiety in Patients With Head & Neck Cancer Not yet recruiting NCT04977271 Phase 4 Venlafaxine
38 Assessing Quality of Life and the Feasibility of a Nutrition and Pharmacological Algorithm for Oncology Patients With Anorexia Terminated NCT04155008 Phase 4 Dexamethasone;Dronabinol;Mirtazapine
39 Randomized Phase IV Trial to Compare Cetuximab With Concomitant Radiation Therapy With Concomitant Mitomycin-C and 5-Fluorouracil With Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Terminated NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
40 Use of Single Dose Pre-Operative Pregabalin for Post-Operative Analgesia in Bilateral Head and Neck Cancer Surgery: A Randomized, Double-Blinded, Placebo-Controlled Trial Withdrawn NCT03714867 Phase 4 Pregabalin 150mg
41 Prospective, Open-label, Randomized, Control Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine Withdrawn NCT01288625 Phase 4 Amifostine
42 The Influence of Glutamine on the Side Effects of Chemo-radiation in Head and Neck Cancer Patients - A Randomized Controlled Trial Unknown status NCT02282839 Phase 3
43 A Multi-centre Randomised Phase III Trial Comparing PET-CT Guided Watch and Wait Policy Versus Planned Neck Dissection for the Management of Locally Advanced (N2/N3) Nodal Metastases in Patients With Head and Neck Squamous Cancer Unknown status NCT00720070 Phase 3
44 A Multicentre Randomised Study Of Parotid Sparing Intensity Modulated Radiotherapy Versus Conventional Radiotherapy In Patients With Head And Neck Cancer Unknown status NCT00081029 Phase 3
45 RANDOMIZED TRIAL OF NEOADJUVANT CHEMOTHERAPY AND SURGERY +/- RADIOTHERAPY VERSUS SURGEERY +/- RADIOTHERAPY IN OPERABLE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY Unknown status NCT00002747 Phase 3 cisplatin;fluorouracil
46 Randomised Clinical Phase III Study of Radiotherapy Dose, Volume Evaluation for 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Squamous Cell Carcinoma Unknown status NCT01124409 Phase 3
47 the Role of COX-2 Inhibitor(CELECOXIB) in Combination With Chemoradiation in Locally Advanced Head & Neck Carcinoma, Phase III Randomized Clinical Trial Unknown status NCT00603759 Phase 3 celecoxib;placebo
48 Standard Radiotherapy Versus Concurrent Chemo-Radiotherapy Followed by Adjuvant Chemotherapy for Locally Advanced (Non-Metastatic) Nasopharyngeal Cancer Unknown status NCT00003637 Phase 3 cisplatin;fluorouracil
49 A Multinational, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancy Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
50 Controlled Randomized Trial to Evaluate Efficacy of Adjuvant Chemotherapy Between S-1 and UFT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Phase III Study Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil

Search NIH Clinical Center for Head and Neck Cancer

Cochrane evidence based reviews: head and neck neoplasms

Genetic Tests for Head and Neck Cancer

Anatomical Context for Head and Neck Cancer

Organs/tissues related to Head and Neck Cancer:

MalaCards : Lymph Node, Salivary Gland, Skin, Lung, Thyroid, Tongue, Breast

Publications for Head and Neck Cancer

Articles related to Head and Neck Cancer:

(show top 50) (show all 27233)
# Title Authors PMID Year
1
A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer. 62 5
23578570 2013
2
A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer. 62 5
23408298 2013
3
Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study. 62 5
21274259 2010
4
Impact of Nutrition Counseling in Head and Neck Cancer Sufferers Undergoing Antineoplastic Therapy: A Randomized Controlled Pilot Study. 62 41
36290823 2022
5
Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy. 5
24934779 2016
6
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 5
25157968 2014
7
Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. 5
23786770 2013
8
MicroRNA expression profiles in head and neck cancer cell lines. 62 46
17475218 2007
9
A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. 41
36279618 2022
10
A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC. 41
36434392 2022
11
Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis. 46
20369013 2010
12
Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. 46
19782034 2009
13
Real-time expression profiling of microRNA precursors in human cancer cell lines. 46
16192569 2005
14
Time-dependent diffusivity and kurtosis in phantoms and patients with head and neck cancer. 62
36219464 2023
15
Suicide risk after head and neck cancer diagnosis in Taiwan: A retrospective cohort study. 62
36198362 2023
16
Assessing Physical and Cognitive Function in Individuals With Head and Neck Cancer: A Feasibility Study. 62
35025776 2023
17
Cobas HPV Genotyping of FNA Sample Supernatant and Frozen Section Scrapings of Suspected Head and Neck Cancer. 62
36121288 2023
18
Family Caregivers' Experiences of Caring for Patients With Head and Neck Cancer: A Systematic Review and Metasynthesis of Qualitative Studies. 62
35439200 2023
19
Concordant palliative care delivery in advanced head and neck cancer. 62
36302326 2023
20
Strategic Reduction of Package Time in Head and Neck Cancer. 62
36407682 2023
21
Head and Neck Cancer-Related Pain. 62
36404073 2023
22
Associative learning contributes to the persistence of fatigue-like behavior in male mice in a model of cancer survivorship. 62
36323360 2023
23
Jehovah's witness head and neck free flap reconstruction patient outcomes. 62
36335661 2023
24
Considerations regarding carotid artery dose in radiotherapy of the cervical spine. 62
36388246 2023
25
Convulsive Syncope From Carotid Sinus Syndrome as a Manifestation of Laryngeal Cancer. 62
35130751 2023
26
Randomized Control Study of the Effects of Turmeric Mouthwash on Oral Health Status, Treatment-Induced Mucositis, and Associated Oral Dysfunctions Among Patients With Head and Neck Cancer. 62
36066336 2023
27
Attitudes Toward and Acceptability of Medical Marijuana Use Among Head and Neck Cancer Patients. 62
35094599 2023
28
MF-094 nanodelivery inhibits oral squamous cell carcinoma by targeting USP30. 62
36474192 2022
29
Comparison of methods for the handling of metallic dental restorations before head and neck radiotherapy. 62
36239800 2022
30
Effect of irradiation on cytokine production in cancer patients. 62
35929109 2022
31
Effect of cisplatin on oral ulcer-induced nociception in rats. 62
36265393 2022
32
Swallowing: A delayed milestone post-surgery in tongue cancers. 62
36356388 2022
33
Autologous platelet concentrates in extraction sockets for the prevention of osteoradionecrosis: a systematic review of controlled clinical trials. 62
35048208 2022
34
A novel technique for the treatment of radiation-induced acquired esophageal atresia in patients with head and neck cancer. 62
36467535 2022
35
High-Accuracy Nodal Staging of Head and Neck Cancer With USPIO-Enhanced MRI: A New Reading Algorithm Based on Node-to-Node Matched Histopathology. 62
35776432 2022
36
Hospital Markup in Head and Neck Cancer Surgery in the US. 62
36301556 2022
37
Head-to-Head Comparison of [68 Ga]Ga-FAPI-46-PET/CT and [18F]F-FDG-PET/CT for Radiotherapy Planning in Head and Neck Cancer. 62
35771317 2022
38
Severe obstructive sleep apnea after concurrent chemoradiotherapy for laryngeal and hypopharyngeal cancer managed by CPAP. 62
34108099 2022
39
Neoadjuvant immunoradiotherapy in patients with locally advanced oral cavity squamous cell carcinoma: a retrospective study. 62
35972629 2022
40
A novel cell-based transplantation method using a Rho kinase inhibitor and a specific catheter device for the treatment of salivary gland damage after head and neck radiotherapy. 62
36386443 2022
41
Prophylactic feeding tube placement for squamous cell carcinoma of the head and neck. 62
36326521 2022
42
Radiotherapy mucositis in head and neck cancer: prevention by low-energy surface laser. 62
31527154 2022
43
Value of p53 sequencing in the prognostication of head and neck cancer: a systematic review and meta-analysis. 62
36456616 2022
44
Head and neck cancer N-glycome traits are cell line and HPV status-dependent. 62
36289103 2022
45
Saliva-based cell-free DNA and cell-free mitochondrial DNA in head and neck cancers have promising screening and early detection role. 62
36459078 2022
46
Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment. 62
36456755 2022
47
Selected ALKBH dioxygenases are overexpressed in salivary gland tumours. 62
36459535 2022
48
A phase Ⅱ prospective trial of photobiomodulation therapy in limiting oral mucositis in the treatment of locally advanced head and neck cancer patients. 62
36474663 2022
49
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048. 62
36264378 2022
50
Osteoradionecrosis versus Cancer Recurrence: An Unresolved Clinical Dilemma. 62
36455537 2022

Variations for Head and Neck Cancer

ClinVar genetic disease variations for Head and Neck Cancer:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 EGFR NM_005228.5(EGFR):c.2527G>A (p.Val843Ile) SNV Likely Pathogenic
376212 rs146795390 GRCh37: 7:55259469-55259469
GRCh38: 7:55191776-55191776
2 EGFR NM_005228.5(EGFR):c.1636C>T (p.Pro546Ser) SNV Likely Pathogenic
376211 rs1057519830 GRCh37: 7:55231430-55231430
GRCh38: 7:55163737-55163737
3 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln) SNV Likely Pathogenic
375896 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
4 EGFR NM_005228.5(EGFR):c.2257C>T (p.Pro753Ser) SNV Likely Pathogenic
376081 rs121913231 GRCh37: 7:55242487-55242487
GRCh38: 7:55174794-55174794
5 TP53 NM_000546.6(TP53):c.916C>T (p.Arg306Ter) SNV Likely Pathogenic
142144 rs121913344 GRCh37: 17:7577022-7577022
GRCh38: 17:7673704-7673704
6 FGFR2 NM_000141.5(FGFR2):c.758C>G (p.Pro253Arg) SNV Likely Pathogenic
13273 rs77543610 GRCh37: 10:123279674-123279674
GRCh38: 10:121520160-121520160
7 SCIMP, ZNF594-DT NM_207103.3(SCIMP):c.99T>C (p.Gly33=) SNV Uncertain Significance
813014 rs2641256 GRCh37: 17:5126674-5126674
GRCh38: 17:5223379-5223379
8 DCDC1 NM_001387274.1(DCDC1):c.247G>A (p.Val83Met) SNV Uncertain Significance
813015 rs2761591 GRCh37: 11:31329373-31329373
GRCh38: 11:31307826-31307826
9 APEX1 NM_001641.4(APEX1):c.259G>C (p.Glu87Gln) SNV Not Provided
443999 rs762384959 GRCh37: 14:20924839-20924839
GRCh38: 14:20456680-20456680

Expression for Head and Neck Cancer

Search GEO for disease gene expression data for Head and Neck Cancer.

Pathways for Head and Neck Cancer

GO Terms for Head and Neck Cancer

Cellular components related to Head and Neck Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.6 MIR99A MIR31 MIR210 MIR21 MIR205 MIR204

Biological processes related to Head and Neck Cancer according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein kinase B signaling GO:0051897 9.97 PIK3CA MIR21 MIR199A1 EGFR
2 gland morphogenesis GO:0022612 9.86 PLAG1 FGFR2
3 negative regulation of gene expression GO:0010629 9.86 TP53 PLAG1 PIK3CA MIR21 MIR205 MIR199A1
4 miRNA-mediated gene silencing GO:0035195 9.86 MIR99A MIR31 MIR210 MIR21 MIR205 MIR204
5 positive regulation of angiogenesis GO:0045766 9.85 MIR31 MIR210 MIR21 MIR199A1
6 regulation of ERK1 and ERK2 cascade GO:0070372 9.85 MIR145 FGFR2 EGFR
7 negative regulation of cell migration GO:0030336 9.72 MIR145 MIR204 MIR205 MIR21 MIR31
8 positive regulation of cardiac muscle cell proliferation GO:0060045 9.71 MIR204 MIR199A1 FGFR2
9 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.65 MIR205 MIR199A1 MIR196A1
10 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.61 MIR21 MIR199A1 MIR145
11 negative regulation of inflammatory response GO:0050728 9.55 MIR31 MIR205 MIR204 MIR199A1 MIR145
12 positive regulation of miRNA maturation GO:1903800 9.54 TP53 EGFR
13 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.52 MIR210 MIR21
14 positive regulation of metalloendopeptidase activity GO:1904685 9.51 MIR21 MIR205
15 positive regulation of cellular response to hypoxia GO:1900039 9.37 MIR21 MIR145
16 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.1 MIR31 MIR210 MIR21 MIR205 MIR204 MIR145

Molecular functions related to Head and Neck Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.65 TP53 MIR31 MIR210 MIR21 MIR205 MIR204
2 mRNA base-pairing translational repressor activity GO:1903231 9.32 MIR99A MIR31 MIR210 MIR21 MIR205 MIR204

Sources for Head and Neck Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....